New and Future Parenteral Therapies for the Management of Lipid Disorders.


Piedmont Heart Institute in Atlanta, Atlanta, GA, USA. Electronic address: [Email]


Cardiovascular disease (CVD) is the leading cause of death in the world. According to the World Health Organization, an estimated 17.9 million people died from CVD in 2016, representing 31% of all global deaths. Of these deaths, 5% are due to myocardial infarction and stroke. Dyslipidemia is known as the major risk factor of atherosclerotic cardiovascular disease. With current therapies, about 60% of high-risk CVD patients do not achieve LDL-C goals, and in patients with familiar hypercholesterolemia (FH) at maximum intensity statin treatment, only 20% achieve LDL-C goals. We discuss new and future parenteral therapies for the management of lipid disorders.


Alipogene,Antisense oligonucleotides,Cardiovascular disease,Dyslipidemia,Inclinsiran,LDL,Lipid disorders therapy,PCSK9,sIRNA,

OUR Recent Articles